Introduction
Heart failure (HF) is one of the diseases with the greatest healthcare expenditure. 1 The most important reason for this huge healthcare burden is recurrent unplanned HF hospitalization.
1,2
Therefore, outpatient visits are becoming more frequently used to treat HF symptoms and optimize medical treatment, including alteration of diuretic doses and initiation/up-titration of neurohormonal antagonists, with an effective impact in reducing HF hospitalizations. 3 Patients hospitalized for HF have poorer prognosis compared with lower risk, ambulatory patients. 4 However, retrospective and post-hoc data derived from clinical trials suggest that patients managed for HF symptoms in the outpatient setting may have similarly adverse prognosis compared to those managed as inpatients. 5, 6 The BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) was a multicentre, multinational, European registry enrolling patients with HF and suboptimal medical treatment, either hospitalized or as outpatients. 7 It therefore allows the assessment of the clinical and prognostic differences of HF patients whether they have been hospitalized or not. Moreover, the identification of outpatients with a similar event risk as inpatients would facilitate the selection of a wider population for future studies and randomized controlled trials without reducing the estimated event rate and consequently not compromising the statistical power for assessing a potential treatment effect. 8 The aims of the present analysis are (i) to compare the characteristics of patients enrolled as inpatients to those enrolled as outpatients; (ii) to use the BIOSTAT-CHF risk score 9 to assess the event risk of both inpatients and outpatients; and (iii) to compare inpatients and outpatients according to the individual patient risk.
Methods

Patient population and risk model development
BIOSTAT-CHF is a European project that enrolled 2516 HF patients from 69 centres in 11 European countries to determine profiles of patients with HF that do not respond to recommended therapies, despite anticipated up-titration. The design and first results of the study and patients have been described elsewhere 7 . In brief, patients were aged ≥ 18 years with signs and symptoms of HF, confirmed either by a left ventricular ejection fraction (LVEF) of ≤ 40% or a brain natriuretic peptide (BNP) and/or N-terminal pro-BNP (NT-proBNP) plasma level > 400 pg/mL and/or > 2000 pg/mL, respectively. Patients needed to be treated with either oral or intravenous furosemide ≥ 40 mg daily or equivalent at the time of inclusion. Patients should not have been previously treated with evidence-based therapies [angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) and beta-blockers], or were receiving < 50% of the target doses of at least one of these drugs at the time of inclusion. 10, 11 The first 3 months of treatment were considered to be the optimization phase after which a stabilization phase of 6 months was defined. During the optimization phase, initiation or up-titration of ACEi/ARB and/or beta-blocker was performed according to the routine clinical practice of the treating physicians, who were encouraged to follow the European Society of Cardiology (ESC) guidelines at the time of
treatment. 10, 11 Patients reaching at least 50% of the recommended dose of ACEi/ARB and/or beta-blocker were considered successfully up-titrated.
The recruitment period was 24 months, starting from December 2010. The last patient was included on 15 December 2012. The median follow-up was 21 months. The primary outcome was a composite of HF hospitalization and all-cause death. The components of the primary outcome were also assessed separately as exploratory outcomes. The adjudication of HF hospitalization was performed by the treating physician. After the trial has ended, all medical reports of the deadly event were read and adjudicated by an independent committee of cardiologists and cardiovascular death was also possible to ascertain.
Ethics Board approval was obtained and all participants signed written informed consent before entering the study. The BIOSTAT-CHF risk models have been previously developed and validated. 9 
Validation cohort
The findings presented herein were also externally validated. The BIOSTAT-CHF validation cohort was designed as a multicentre, prospective, observational study. The study population consisted of 1738 patients from six centres in Scotland, UK. The recruitment period started in October 2010 and was completed in April 2014. Median follow-up was 21 months. Patients from the validation cohort were aged > 18 years with a HF diagnosis based on echocardiographic evidence of left ventricular dysfunction or a previous documented admission with HF treated with furosemide ≥ 20 mg daily or equivalent, not previously treated or receiving ≤ 50% of target doses of ACEi/ARB and/or beta-blocker according to the 2008 ESC guidelines. 11 Patients could be enrolled as inpatients or from outpatient clinics. 7 
Statistical analysis
Population description and comparison of outpatients vs. inpatients was performed using t-test, Mann-Whitney or chi-square test, as appropriate. Cox proportional hazard regression models were used to model long-term event rate of the variables included in the previously published BIOSTAT-CHF risk models. 9 Proportional hazard assumption was verified graphically using 'log-log' plots. Log-linearity was checked by testing the functional forms of the covariable by the Kolmogorov-type supremum test and by visual inspection by plotting the beta estimates vs. the mean across quintiles. Missing predictor values were imputed using multichain Monte Carlo methods with Gibbs sampling. 9 We imputed missing data five times, performed the analysis over all five imputations, and averaged results using Rubin's rules. 12 An integer-point risk score was created to assess each patient individual risk and allow the comparison of outpatients to inpatients according to their probability of future events. In order to create a simple integer risk score, continuous variables included in the chosen model were categorized into either two or three groups using a combination of established clinical cut-points and graphical examination of rates across quintiles. To simplify the risk score, integer points were assigned to each prognostic factor based upon the log-hazard ratio (HR) estimates. The total risk score for each patient was calculated by summing the points across all chosen prognostic variables. From the overall distribution of the risk score, we formed three categories (tertiles) of risk, containing approximately equal number of events. Within each risk category, we calculated the number of events, person-years at risk, and the overall event rate. Kaplan-Meier plots were drawn showing the cumulative incidence curves of outpatients vs. inpatients and risk category.
The covariates used for adjustment when comparing the HR of inpatients vs. outpatients were chosen from demographic (age and gender), clinical (previous HF hospitalization, use of beta-blockers and systolic blood pressure), and laboratory [NT-proBNP, blood urea nitrogen, haemoglobin, high-density lipoprotein (HDL) cholesterol, estimated glomerular filtration rate (eGFR) by the Chronic Kidney Disease Epidemiology Collaboration formula, 13, 14 and sodium]. All these parameters were previously found to be independently associated with the outcomes in the BIOSTAT-CHF cohort and were the parameters used to build the risk models depicted herein (https://biostat-chf.shinyapps .io/calc/). 9 The BIOSTAT-CHF risk models were externally validated and showed good internal calibration and consistency across levels of risk and geographical regions. 9 Hospitalization for HF was analysed using a competing risk model (accounting for death as competing risk), as described by Fine and Gray. 15 All the analyses were performed using STATA version 14 (Stata Corp., College Station, TX, USA). A P-value < 0.05 was considered statistically significant.
Results
Characteristics of the study population
A total of 2516 patients were analysed, 822 as outpatients and 1694 as inpatients. The mean age was ∼ 68 years and > 70% were male. Compared to HF outpatients, in-hospital enrolled patients had higher heart rate, urea, NT-proBNP, lower blood pressure, lower eGFR, sodium, potassium, HDL-cholesterol, had more often peripheral oedema, rales, orthopnoea, elevated jugular venous pressure, New York Heart Association class III or IV, new-onset HF admission, diabetes, anaemia, and were less often treated with beta-blockers and ACEi/ARB ( Table 1) . Age and LVEF were similar between groups and outpatients had been more often hospitalized for HF in the previous year and had beta-blockers and/or ACEi/ARB up-titrated more often ( Table 1) .
Outcome associations
Compared to HF outpatients, inpatients had higher rates of primary outcome events [adjusted HR 1.24 , 95% confidence interval (CI) 1.07- 1.43 ] and HF hospitalization events (1.38, 95% CI 1.14-1.66), but not mortality (1.11, 95% CI 0.92-1.34) ( Table 2) . The Kaplan-Meier curves for the primary outcomes are shown in Figure 1 .
Outpatients had 247 (30%) primary outcome events, 152 (18%) HF hospitalization events, and 155 (19%) deaths, with corresponding incidence rates per 100 person-years of 18.5 (95% CI 16.4-21.0), 11.4 (95% CI 9.7-13.3), and 10.4 (95% CI 9.0-12.3). Inpatients had 767 (45%) primary outcome events, 456 (27%) HF hospitalization events, and 502 (27%) deaths, with corresponding incidence rates per 100 person-years of 33. 4 ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HF, heart failure; HFH, hospitalization for heart failure; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure. * Up-titration period occurred during the first 3 months after inclusion in the study, hence patients who died or that were lost to follow-up were excluded from the up-titration analysis (see Methods section). 
Risk model
The integer score derived from the BIOSTAT-CHF risk model provided a maximum of 15 points ( Table 3) . Dividing the risk score in tertiles, we classified patients as: from 0 to 4 points = low risk (n = 1058); 5 to 6 points = intermediate risk (n = 746); 7 to 15 points = high risk (n = 712).
Incidence rates by risk categories
The primary outcome incidence rates per 100 person-years according to the risk categories were: low-risk = 11. Figure 2) . Incidence rates for the individual components of the primary outcome are depicted in Table 4 . Outpatients in the intermediate and high-risk categories had similar event rates compared to inpatients overall ( Figure 3) . 
External validation
Cardiovascular mortality
Cardiovascular mortality represented 67% (441/657) of all deaths. The associations for cardiovascular mortality were similar to those above described for all-cause mortality (online supplementary Tables S4 and S5). The associations for the outcome of cardiovascular mortality or HF hospitalization were similar to those above described for the primary outcome (data not shown).
Discussion
The present study shows that HF inpatients were different from outpatients. Inpatients had more co-morbidities and higher overall event rates. However, outpatients classified as having intermediate and/or high risk had similar event rates compared to the inpatient overall population. Nevertheless, it should be noted that more than half (53%) of outpatients were classified as 'low-risk' with corresponding low event rates that may not be suitable for a HF trial. In addition, the outcome difference between outpatients and inpatients was mainly observed due to differences in hospitalization rates. These data demonstrate that HF outpatients are patients at high risk of major events and should also be considered to be included in trials, as they may present similar risk to inpatients. Moreover, symptomatic HF in the outpatient setting could also be considered for incorporation in the composite primary outcome of contemporary trials, providing more detailed events (e.g. intravenous diuretic administration and/or need for increasing oral . diuretics) available for adjudication. Moreover, the simple integer score generated in the present analysis provides a 'ready-to-use' tool for enhancing patient risk in future HF studies, particularly for outpatient selection − selecting intermediate to high-risk outpatients based on our risk score allows the selection of a HF population with similar event rates compared to hospitalized patients.
Figure 2
Incidence rates per 100 person-years for the primary outcome of heart failure hospitalization or death by tertiles of risk score.
Figure 3
Incidence rates per 100 person-years for the primary outcome of heart failure hospitalization or death with comparison of outpatient risk levels with inpatient overall risk.
These findings were replicated externally. To the best of our knowledge, this is the first study to compare outpatients vs. inpatients by levels of individual risk. Many patients with symptomatic HF have a gradual evolution of congestive signs and symptoms, offering a potential window in which effective therapy may abort continued worsening and prevent the need for hospitalization. 16 Additionally, the so-called focus should be provided to HF outpatients (e.g. in 'intravenous diuretic clinics') as interventions in this setting may avoid downstream hospitalizations. 16 Outpatients may also be more suitable for medication up-titration as they may be less symptomatic and present less co-morbid conditions. 16 This assumption was corroborated in the present analysis in which HF outpatients had less co-morbidities and were more often up-titrated to target doses for both beta-blockers and ACEi/ARB. Outpatients were admitted less frequently as 'new-onset' HF. This is likely due to the fact that only patients with known HF history are referenced for HF clinics. It should be noted that patients with new-onset HF likely have improved survival compared to patients with chronic HF diagnoses, 18 however the higher proportion of new-onset HF patients in the inpatient group did not reduce the overall risk of this population, nor this variable was retained in the 'best' risk model.
The event rates observed in the BIOSTAT-CHF study (including the validation cohort) were superior to those observed in contemporary chronic HF randomized controlled trials but overlapped those observed in acute HF trials and registries.
19 -22 For example, the event rates per 100 person-years observed in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF) 19 for the primary outcome of HF hospitalization or cardiovascular death varied from 9 to 15 events per 100 person-years (depending on the geographic region 23 ), which were lower than those we observed in BIOSTAT-HF for outpatients (16 to 21 events per 100 person-years) and nearly half of the event rates observed for inpatients (31 to 36 events per 100 person-years). However, we must consider the different inclusion criteria of the two studies, chronic stable HF in PARADIGM-HF vs. symptomatic and under-treated HF in BIOSTAT-CHF, and that cardiovascular, rather than all-cause, mortality was assessed as a component of the primary endpoint in PARADIGM-HF. Comparable event rates were only observed in the lower risk category of the BIOSTAT-CHF (10 to 13 events per 100 person-years). The event rates observed in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) trial 24 were also much lower compared to those observed in BIOSTAT-CHF, with only the high-risk patients in the placebo group in the EMPHASIS-HF having similar event rates (for the primary outcome of cardiovascular death or HF hospitalization) to those observed in inpatients from BIOSTAT-CHF (∼ 39 per 100 person-years). 25 These findings suggest that patients with HF enrolled in BIOSTAT-CHF were more severe than those enrolled in contemporary chronic HF trials. However, HF symptoms were not needed at the time of enrolment in these trials, and patients were younger, less symptomatic and with less co-morbidities than those enrolled in BIOSTAT-CHF.
19,24
The proportion of events observed in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial, in a median follow-up of 10 months, overlapped that observed in BIOSTAT-CHF. The EVEREST trial (tolvaptan vs. placebo) was neutral, and 41% of patients experienced cardiovascular death or HF hospitalization and 26% died from any cause. 21 This proportion of events is similar to that observed in the intermediate risk of the BIOSTAT-CHF population, both for inpatients and outpatients. In the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) trial, during a median follow-up of 11 months there were no statistically significant differences between aliskiren and placebo in events, and 25% of patients died from cardiovascular causes or were hospitalized for HF, and 18% died from any cause. 22 The proportion of events in the ASTRONAUT trial is more similar to that observed in the low- 20 These findings suggest that outpatients with HF signs and symptoms plus elevated natriuretic peptides are also a high-risk population. 6 As stated in the protocol, dose up-titration to target doses of evidence-based therapies was always recommended. However, only 53% and 40% of the patients reached ≥ 50% of the target doses of ACEi/ARB and beta-blockers, respectively. Not reaching ≥ 50% of the target dose of ACEi/ARB or beta-blockers was associated with worse outcomes (compared with patients who reached > 50% of the target dose). 26 Mineralocorticoid receptor antagonists remained extensively underused throughout the study. 27 In the present analysis we also found that the higher event rates observed in inpatients was mostly due to the burden of HF hospitalization (with similar rates for outpatients in intermediate/high-risk categories). Hence, reducing HF symptoms and the burden of hospitalizations is an important target of any HF intervention or therapy. 19, 24, 28 However, this also shows that HF hospitalization and mortality may be dissociated in the clinical course of HF patients and that the variables related with HF hospitalization may differ from those related with mortality. 29 In the present study, cardiovascular mortality represented 67% of all deaths, and the associations described for all-cause death are similar to those observed for cardiovascular mortality.
Risk enhancement strategies are used in HF trials and registries in order to increase the specificity for the presence of HF and the odds of subsequent events necessary to ascertain prognostic associations and/or treatment effect with adequate power and precision. Hence, many studies include only patients hospitalized for HF as these have higher risk for subsequent events. 19, 30 Moreover, natriuretic peptide thresholds are increasingly used with both purposes of increasing HF specificity and risk. 19, 28, 29 In the present study we demonstrate that a high proportion of outpatients have similar risk as inpatients. Due to the high event rate in these outpatients with HF, they might also be a target for better future therapies. In this regard, the present study provides a useful tool for 'risk enhancement' in futures HF studies and trials.
Limitations
Several limitations should be acknowledged in this analysis. First, this is a post-hoc analysis of a prospective, non-randomized observational study, therefore all limitations inherent to such analysis are applied herein, including the inability to infer causality. Second, the data from BIOSTAT-CHF come from European centres only and may not be representative of HF patients in other world regions. Third, all patients enrolled in BIOSTAT-CHF had severe symptoms and high natriuretic peptide levels, hence these findings cannot be generalized to less symptomatic HF patients. Fourth, the proportion of patients (especially outpatients) with LVEF > 40% was very low (4% to 12%) and these results cannot be generalized to patients with mid-range or preserved LVEF. Lastly, intravenous diuretic use was not registered in the outpatient setting, hence we cannot ascertain how many of these patients could be considered as true worsening HF.
Conclusions
Marked differences were observed between inpatients and outpatients with HF. Overall, inpatients were sicker and had higher event rates. However, a substantial proportion of outpatients had similar or higher event rates compared to inpatients. These findings suggest that HF outpatients, usually not enrolled in HF trials nor considered as endpoints, also have poor prognosis and may be the focus of future trials.
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